Table 1 |
||||||
|
Demographic data of subjects |
||||||
|
Parameter |
Sequence |
N |
Mean |
SD |
Median |
Range |
|
|
||||||
|
Age (years) |
BE |
20 |
23.9 |
3.65 |
23.5 |
20; 35 |
|
EA |
20 |
25.1 |
5.01 |
24.0 |
20; 39 |
|
|
AEB |
20 |
27.8 |
6.57 |
26.5 |
20; 45 |
|
|
|
||||||
|
Weight (kg) |
BE |
20 |
68.3 |
10.74 |
69.5 |
50; 90 |
|
EA |
20 |
67.7 |
9.54 |
68.5 |
49; 82 |
|
|
AEB |
20 |
67.9 |
10.48 |
68.0 |
52; 87 |
|
|
|
||||||
|
BMI (kg/m2) * |
BE |
20 |
22.8 |
2.40 |
23.0 |
19; 27 |
|
EA |
20 |
22.9 |
2.29 |
23.0 |
19; 27 |
|
|
AEB |
20 |
22.2 |
2.67 |
22.0 |
19; 27 |
|
|
|
||||||
|
|
||||||
|
Sequence |
N |
N (♀) |
% (♀) |
N (♂) |
% (♂) |
|
|
|
||||||
|
Female gender (%) |
BE |
20 |
7 |
35.0 |
13 |
65.0 |
|
EA |
20 |
6 |
30.0 |
14 |
70.0 |
|
|
AEB |
20 |
6 |
30.0 |
14 |
70.0 |
|
|
|
||||||
|
Demography and other baseline characteristics by treatment sequence (Pharmacokinetic population; N = 60). "A" refers to Nurofen® forte, "B" refers to Migränin® and "E" refers to Eudorlin® extra. * calculated from measured height (m) and weight (kg). |
||||||
|
Bramlage and Goldis BMC Pharmacology 2008 8:18 doi:10.1186/1471-2210-8-18 |
||||||
